About Actuate Therapeutics Inc
https://actuatetherapeutics.comActuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
CEO
Daniel M. Schmitt
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:10.05M
Value:$52.86M
VOSS CAPITAL, LLC
Shares:896.28K
Value:$4.71M
VANGUARD GROUP INC
Shares:316.01K
Value:$1.66M
Summary
Showing Top 3 of 44
About Actuate Therapeutics Inc
https://actuatetherapeutics.comActuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.47M ▼ | $-5.41M ▲ | 0% | $-0.25 ▲ | $-5.4M ▲ |
| Q2-2025 | $0 | $5.97M ▼ | $-5.95M ▲ | 0% | $-0.3 ▲ | $-5.94M ▲ |
| Q1-2025 | $0 | $6.37M ▼ | $-6.32M ▲ | 0% | $-0.32 ▲ | $-6.31M ▲ |
| Q4-2024 | $0 | $6.56M ▲ | $-6.45M ▼ | 0% | $-0.6 ▼ | $-6.32M ▼ |
| Q3-2024 | $0 | $5.39M | $-5.97M | 0% | $-0.55 | $-5.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $16.92M ▲ | $17.71M ▲ | $6.78M ▼ | $10.94M ▲ |
| Q2-2025 | $6.49M ▲ | $6.97M ▲ | $9.62M ▲ | $-2.65M ▲ |
| Q1-2025 | $3.89M ▼ | $4.48M ▼ | $9.57M ▲ | $-5.09M ▼ |
| Q4-2024 | $8.64M ▼ | $9.32M ▼ | $9.21M ▲ | $104.19K ▼ |
| Q3-2024 | $13.52M | $14.26M | $8.9M | $5.36M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.41M ▲ | $-6.68M ▼ | $0 | $17.11M ▲ | $10.43M ▲ | $-6.68M ▼ |
| Q2-2025 | $-5.95M ▲ | $-4.35M ▲ | $0 | $6.95M ▲ | $2.6M ▲ | $-4.35M ▲ |
| Q1-2025 | $-6.32M ▲ | $-4.62M ▲ | $0 | $-133.48K ▼ | $-4.75M ▲ | $-4.62M ▲ |
| Q4-2024 | $-6.45M ▼ | $-4.77M ▲ | $0 | $-109.41K ▼ | $-4.88M ▼ | $-4.77M ▲ |
| Q3-2024 | $-5.97M | $-9.15M | $0 | $22.32M | $13.17M | $-9.15M |
CEO
Daniel M. Schmitt
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:10.05M
Value:$52.86M
VOSS CAPITAL, LLC
Shares:896.28K
Value:$4.71M
VANGUARD GROUP INC
Shares:316.01K
Value:$1.66M
Summary
Showing Top 3 of 44